A Pilot Trial of Using Pre-Transplant Risk Stratification and Prophylactic Defibrotide to Prevent Serious Thrombotic Microangiopathy in High-Risk Hematopoietic Stem Cell Transplant Patients
Latest Information Update: 18 May 2022
At a glance
- Drugs Defibrotide (Primary) ; Carboplatin; Cyclophosphamide; Etoposide; Melphalan; Thiotepa
- Indications Thrombotic microangiopathy
- Focus Adverse reactions; Therapeutic Use
- 01 May 2022 Results assessing the safety and feasibility of administering prophylactic defibrotide to high-risk pediatric patients during HSCT and assessed if prophylactic defibrotide prevented TA-TMA compared to historic controls published in the Pediatric Blood and Cancer
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 16 Nov 2020 Status changed from recruiting to completed.